Monoclonal antibody therapy in multiple myeloma.

摘要: The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the past decade with discovery and validation proteasome inhibitors immunomodulatory agents as highly active agents, both in front-line therapy well relapse maintenance settings. Although previous attempts to apply available monoclonal antibodies (Mabs) treatment patients MM until recently been disappointing, novel targets specifically explored context have lead first approvals Mabs for MM. We performed a literature search identify preclinical targeting MM, including vitro vivo models using antibodies, clinical trials Sources used were peer-reviewed publications, congress abstracts on-line data (such clinicaltrials.gov). Several evaluated growing number are being trials, single or combination under various antibody formats. Two time CD38 SLAMF7, respectively, approved recent approval these two is expected strong impact on modalities outcome transplant eligible elderly patients.